SATELLITE SYMPOSIA SCHEDULE and AGENDA (as of May 15, 2017)

Transcription

1 14-ICML - 14 th INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA Lugano, Switzerland June 14-17, SATELLITE SYMPOSIA SCHEDULE and AGENDA (as of May 15, 2017) Tuesday, June 13, :00 14:00 2 parallel symposia Room BI CELLTRION HEALTHCARE THE 1ST BIOSIMILAR RITUXIMAB BASED ON CLINICAL EVIDENCE Chair: C. Buske, Ulm (Germany) 12:00 12:20 WELCOME AND INTRODUCTION: PERCEPTUAL EVOLUTION ON BIOSIMILAR C. Buske, Ulm (Germany) 12:20 12:40 REDUCING BUDGETS, INCREASING ACCESS L. Gulácsi, Budapest (Hungary) 12:40 13:10 THE RATIONALE OF BIOSIMILARITY J. Gonçalves, Lisboa (Portugal) 13:10 13:40 CLINICAL EVIDENCE OF BIOSIMILAR RITUXIMAB W.S. Kim, Seoul (South Korea) 13:40 14:00 BIOSIMILAR IN ONCOLOGY: YESTERDAY, TODAY AND A LOOK AHEAD Panel Discussion Room BII NOVARTIS PHARMACEUTICALS CORPORATION CHALLENGES AND OPPORTUNITIES IN THE MANAGEMENT OF AGGRESSIVE B CELL LYMPHOMAS Chair: S.J. Schuster, Philadelphia, PA (USA) 12:00 12:05 OPENING REMARKS BY THE CHAIR 12:05 12:35 NOVEL APPROACHES IN THE ALGORITHM FOR MANAGEMENT OF AGGRESSIVE B CELL LYMPHOMAS P. Borchmann, Cologne (Germany) 12:35 13:05 AGGRESSIVE B CELL LYMPHOMAS: THE ROLE OF STEM CELL TRANSPLANT IN THE ERA OF TARGETED THERAPIES A. Sureda, Barcelona (Spain) 13:05 13:35 EXPERIENCES FROM THE USE OF INVESTIGATIONAL CAR T CELL THERAPIES IN B CELL LYMPHOMAS S.J. Schuster, Philadelphia, PA (USA) 13:35 14:00 PANEL DISCUSSION

2 15:30 17:30 3 parallel symposia GILEAD SCIENCES ADVANCING PROGNOSTICATION AND TARGETED STRATEGIES IN CLL AND FL Co-chairs: and M. Hallek, Cologne (Germany) 15:30 15:35 WELCOME AND INTRODUCTION 15:35 15:50 DECIPHERING THE MOLECULAR LANDSCAPE IN CLL: NEW TREATMENT CHALLENGES D. Rossi, Bellinzona (Switzerland) 15:50 16:05 UNTANGLING THE COMPLEXITIES OF FL: CURRENT TREATMENT CHALLENGES A. Davies, Southampton (UK) 16:05 16:20 HIGH RISK VERSUS LOW RISK IN FL: PROGNOSTICATION FOR A PRECISION APPROACH B. Kahl, Saint Louis (USA) 16:20 16:30 CROSS-TALK: SIMILARITIES AND DIFFERENCES IN APPROACHES TO RISK STRATIFICATION AND TREATMENT IN CLL AND FL Led by 16:30 16:50 HITTING THE RIGHT TARGETS IN CLL AND FL: FROM PATHWAY TO PRACTICE M. Hallek, Cologne (Germany) and 16:50 17:05 TARGETED TREATMENTS IN CLL AND FL: SEQUENCING OR COMBINATIONS? A. Zelenetz, New York, NY (USA) 17:05 17:25 CROSS-TALK: MAKING INFORMED TREATMENT CHOICES IN CLL AND FL Led by M. Hallek, Cologne (Germany) 17:25 17:30 SUMMARY AND CLOSE M. Hallek, Cologne (Germany) Room B I BRISTOL-MYERS SQUIBB IMMUNO-ONCOLOGY RESEARCH IN LYMPHOMA: PRESENT AND FUTURE Chair: G. Collins, Oxford (UK) 15:30 15:35 WELCOMING REMARKS G. Collins, Oxford (UK) 15:35 15:55 LYMPHOMA IN REVIEW: CHALLENGES IN TODAY S CLINICAL PRACTICE G. Collins, Oxford (UK) 15:55 16:15 ONGOING EXPLORATIONS OF IMMUNO-ONCOLOGY IN CLASSICAL HODGKIN LYMPHOMA P. Brice, Paris (France) 16:15 16:35 PURSUING EXISTING NEEDS THROUGH INVESTIGATIONS IN NON-HODGKIN LYMPHOMA: IMMUNO-ONCOLOGY AND MORE T.M. Illidge, Manchester (UK) 16:35 16:55 LIGHTING THE WAY: INFORMING LYMPHOMA PATHOLOGY WITH BIOMARKER RESEARCH D. de Jong, Amsterdam (The Netherlands)

3 16:55 17:25 OPEN DISCUSSION WITH THE EXPERTS All CLOSING REMARKS Moderated by G. Collins, Oxford (UK) Room B II SERVIER ONCOLOGY MANAGEMENT OF MULTIPLY RELAPSED AGGRESSIVE NHL: NEW PERSPECTIVES Co-chairs: R. Pettengell, London (UK) and E. Van Den Neste, Brussels (Belgium) 15:30-15:35 INTRODUCTION E. Van Den Neste, Brussels (Belgium) 15:35 15:55 TREATMENT LANDSCAPE OF B-CELL-NHL PATIENTS, LOOKING INTO THE FUTURE OF NEW STRATEGIES P.L. Zinzani, Bologna (Italy) 15:55 16:10 PATIENTS WITH RELAPSED DLBCL WHO FAIL SECOND LINE SALVAGE THERAPY: MONOTHERAPY VERSUS COMBINATION THERAPY E. Van Den Neste, Brussels (Belgium) 16:10 16:25 PIXANTRONE FOR THIRD- AND FOURTH-LINE TREATMENT OF RELAPSED/REFRACTORY NON-HODGKIN B-CELL LYMPHOMA R. Pettengell, London (UK) 16:25 16:55 PATIENT CASE 1 A. Hayat, Galway (Ireland) PATIENT CASE 2 K. Hübel, Cologne (Germany) 16:55 17:15 PANEL DISCUSSION 17:15 17:20 CONCLUSION R. Pettengell, London (UK) 19:00 21:00 3 parallel symposia ROCHE IMPROVING TREATMENT STRATEGIES FOR PATIENTS WITH FOLLICULAR LYMPHOMA: HOW TO TRANSLATE NOVEL STUDY DATA INTO CLINICAL PRACTICE Chair: B.D. Cheson, Washington D.C. (USA) 19:00 19:10 WELCOME AND INTRODUCTION B.D. Cheson, Washington D.C. (USA) 19:10 19:35 THE PATIENTS' PERSPECTIVE AND QUALITY OF LIFE IN FOLLICULAR LYMPHOMA R. Pfau, Aesch (Switzerland) 19:35 20:00 HOW CAN WE IMPROVE FIRST-LINE TREATMENT FOR FOLLICULAR LYMPHOMA AND HOW TO MEASURE IMPROVEMENT? M. Rummel, Giessen (Germany) 20:00 20:25 RECENT ADVANCES IN TREATMENT FOR PATIENTS WITH FOLLICULAR LYMPHOMA A. Davies, Southampton (UK) 20:25 20:50 MANAGEMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA IN THE FUTURE

4 20:50 21:00 CLOSING REMARKS B.D. Cheson, Washington D.C. (USA) Room B I BAYER SHIFTING PARADIGMS IN THE MANAGEMENT AND TREATMENT OF INDOLENT NHL* Co-chairs: and M. Dreyling, Munich (Germany) WELCOME and M. Dreyling, Munich (Germany) DIFFERENTIAL BIOLOGY OF PI3K INHIBITORS IN NHL G. Lenz, Muenster (Germany) EMERGING CHEMO-FREE TREATMENT STRATEGIES IN INDOLENT NHL J.P. Leonard, New York, NY (USA) CLINICAL EXPERIENCE WITH COPANLISIB IN RELAPSED/REFRACTORY INDOLENT LYMPHOMA G. Follows, Cambridge (UK) PANEL DISCUSSION/Q&A and M. Dreyling, Munich (Germany) *Copanlisib is an investigational agent currently in clinical trials and is not approved by Swissmedic, the FDA, EMA, or other health authorities. The effi-cacy and safety of copanlisib have not been established. / Bayer (Schweiz) AG, Grubenstrasse 6, 8045 Zurich, Switzerland Room B II TAKEDA ONCOLOGY TARGETING CD30 IN LYMPHOMA: A MARKER FOR CHANGE? Co-chairs: A. Engert, Cologne (Germany) and K.J. Savage, Vancouver (Canada) 19:00 19:05 WELCOME AND INTRODUCTIONS A. Engert, Cologne (Germany) and K.J. Savage, Vancouver (Canada) 19:05 19:25 CD30: FROM DIAGNOSTIC MARKER TO THERAPEUTIC TARGET PANEL DISCUSSION: ROLE OF CD30 A. Engert, Cologne (Germany) and K.J. Savage, Vancouver (Canada) 19:25 19:45 DIRECTING TREATMENT TO CD30-DEFINED MALIGNANCIES: A FOCUS ON RELAPSED/REFRACTORY HODGKIN LYMPHOMA A. Sureda, Barcelona (Spain) 19:45 20:05 BEYOND THE RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENT: WHAT ARE OUR OPTIONS IN THE FRONTLINE SETTING? A. Engert, Cologne (Germany) 20:05 20:25 CD30-POSITIVE PERIPHERAL T-CELL LYMPHOMA K.J. Savage, Vancouver (Canada) 20:25 20:45 CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA S. Horwitz, New York, NY (USA) 20:45 20:55 PANEL DISCUSSION / Q&A SESSION: HOW I TREAT CD30-POSITIVE LYMPHOMA All, led by A. Engert, Cologne (Germany) and K.J. Savage, Vancouver (Canada)

5 20:55 21:00 CONCLUSIONS AND MEETING CLOSE A. Engert, Cologne (Germany) and K.J. Savage, Vancouver (Canada) Wednesday, June 14, :00 21:00 2 parallel symposia JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON CURRENT CONTROVERSIES IN B-CELL LYMPHOMAS: HOW TO MANAGE PATIENTS WITH HIGH UNMET NEEDS Chair: 19:00 19:10 WELCOME AND INTRODUCTION 19:10 19:35 CURRENT DILEMMAS IN DIFFUSE LARGE B-CELL LYMPHOMA G. Lenz, Berlin (Germany) 19:35 19:55 CLINICAL COMPLEXITIES IN MANTLE CELL LYMPHOMA S. Rule, Plymouth (UK) 19:55 20:15 CHALLENGING CASES IN FOLLICULAR LYMPHOMA C. Buske, Ulm (Germany) 20:15 20:30 NEW OPTIONS IN THE MANAGEMENT OF MARGINAL ZONE LYMPHOMA C. Thieblemont, Paris (France) 20:30 20:45 WALDENSTRÖM S MACROGLOBULINEMIA WHERE NEXT? S. Treon, Boston MA (USA) 20:45 21:00 PANEL DISCUSSION AND CLOSING REMARKS and all faculty Room B ABBVIE, INC. NOVEL TREATMENTS IN RELAPSED/REFRACTORY CLL: PRESENT AND FUTURE Chair: U. Jäger, Vienna (Austria) 19:00 19:05 CHAIR S WELCOME AND INTRODUCTION U. Jäger, Vienna (Austria) 19:05 19:15 SETTING THE SCENE: THE BURDEN OF RELAPSED/REFRACTORY CLL U. Jäger, Vienna (Austria) 19:15 19:35 HISTORICAL PERSPECTIVES ON RELAPSED/REFRACTORY CLL THERAPY D. Rossi, Bellinzona (Switzerland) 19:35 20:00 CURRENT TARGETED TREATMENT OPTIONS IN RELAPSED/REFRACTORY CLL B. Eichhorst, Cologne (Germany) 20:00 20:20 NEW AGENTS IN DEVELOPMENT: INNOVATIONS IN RELAPSED/REFRACTORY CLL V. Leblond, Paris (France) 20:20 20:45 ROUNDTABLE DISCUSSIONS All 20:45 20:55 AUDIENCE Q&A

6 All CHAIR S SUMMARY AND CLOSE U. Jäger, Vienna (Austria) Thursday, June 15, :00 21:00 2 parallel symposia CELGENE MANAGEMENT OF B-CELL NON-HODGKIN LYMPHOMA: WHERE ARE WE NOW AND WHERE ARE WE GOING? Chair: 19:00 19:10 WELCOME AND INTRODUCTION 19:10 19:30 HURDLES AND UNMET NEEDS IN THE MANAGEMENT OF INDOLENT NHL 19:30 19:50 PROGRESS AND PROMISE: CURRENT AND FUTURE PERSPECTIVES ON THERAPY OF INDOLENT NHL N.H. Fowler, Houston, TX (USA) 19:50 20:00 Q&A 20:00 20:20 IMPROVING FRONTLINE TREATMENT OUTCOMES IN DLBCL U. Vitolo, Turin (Italy) 20:20 20:40 NEXT GENERATION THERAPIES IN B-CELL NHL: THE ROLE OF PROTEIN HOMEOSTASIS A. Gandhi, Summit, NJ (USA) 20:40 20:50 Q&A 20:50 21:00 CONCLUDING REMARKS Room B MUNDIPHARMA MEDICAL COMPANY - TEVA ONCOLOGY CHEMOTHERAPY IN INDOLENT LYMPHOMA - DYING OR WELL ALIVE? Chair: 19:00 19:05 WELCOME AND INTRODUCTION 19:05 19:25 THE ROLE OF INDUCTION CHEMOTHERAPY FOR THE EFFICACY OF MAINTENANCE IN FOLLICULAR LYMPHOMA M. Dreyling, Munich (Germany) 19:25 19:45 CAN WE FORESEE A CHEMO-FREE TREATMENT FOR FOLLICULAR LYMPHOMA? 19:45 20:00 ROUNDTABLE DISCUSSION 20:00 20:20 CAN WE FORESEE A CHEMO-FREE TREATMENT FOR CHRONIC LYMPHOCYTIC

7 LEUKEMIA? D.M. Brander, Durham, NC (USA) 20:20 20:40 NEW CHEMOTHERAPEUTIC AGENTS FOR LYMPHOMA O. O Connor, New York, NY (USA) 20:40 20:55 ROUNDTABLE DISCUSSION 20:55 21:00 CONCLUSION AND CLOSURE Friday, June 16, :30 19:30 ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND IOSI THE BIG DEBATE: POINT COUNTER POINT HAVE NEW DRUGS MADE STEM CELL TRANSPLANTATION OBSOLETE? Chair: Supported by Gilead Sciences Europe Ltd who provided funding. - CLL: yes: J.G. Gribben, London (UK) vs no: D.G. Maloney, Seattle, WA (USA) - HL: yes: P. Borchmann, Cologne (Germany) vs no: A. Sureda, Barcelona (Spain) - FL: yes: J.P. Leonard, New York, NY (USA) vs no: S. Montoto, London (UK) Room B 18:45 20:45 KITE PHARMA ENGINEERED T-CELL THERAPY: CAR-T S ESTABLISHING A NEW PARADIGM OF TREATMENT IN RELAPSED AND REFRACTORY NHL? Chair: Co-chair: P. Dreger, Heidelberg (Germany) 18:45 19:00 INTRODUCTION AND A REVIEW OF THE CURRENT RELAPSED AND REFRACTORY NHL LANDSCAPE 19:00 19:30 THE IMMUNE SYSTEM, T-CELL BIOLOGY AND THE RATIONALE FOR CAR-T THERAPY J.G. Gribben, London (UK) 19:30 19:55 THE DEVELOPMENT OF KTE-C19, THE FIRST CAR-T DEVELOPED FOR R/R NHL A REVIEW OF FULL DEVELOPMENT THROUGH TO THE ZUMA-1 FINAL ANALYSIS S. Neelapu, Houston, TX (USA) 19:55 20:20 PREPARING THE CENTERS TO MANAGE CAR-T PATIENTS M.J. Kersten, Amsterdam (The Netherlands) 20:20 20:40 ROUNDTABLE Q&A SESSION 20:40 20:45 CLOSING REMARKS P. Dreger, Heidelberg (Germany)